Global Health Investment Fund clears a profit on voucher sale to Novo Nordisk

An innovative financing mechanism for drugs for neglected diseases is providing a return for impact investors. Novo Nordisk, the Danish pharmaceutical giant, disclosed that it is the buyer of a “priority review voucher” from Medicines Development for Global Health, an Australian nonprofit that won U.S. Food and Drug Administration approval for moxidectin as a treatment